V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009020 | 330005811 | 1.79 | null | Palliative (P) | 2018-03-15 | 2018-03-17 | BEP 5 Day | 02 | N | 330023929 | CLADRIBINE |
| 330009021 | 330005812 | null | 9.5 | Palliative (P) | null | 2014-11-01 | DACTINOMYCIN | N | N | 330023929 | IVA |
| 330009022 | 330005816 | 1.62 | null | Palliative (P) | 2018-02-22 | 2018-02-22 | Cytarabine+Methotrexate Intrathecal | N | N | 330023935 | FLUOROURACIL + MITOMYCIN |
| 330009023 | 330005817 | 1.65 | 0 | Palliative (P) | 2016-06-12 | 2016-06-15 | VIDE | N | N | 330023935 | DACTINOMYCIN + VINCRISTINE |
| 330009024 | 330005818 | null | 80.5 | null | 2016-06-08 | 2016-06-13 | Mitotane 4 - 4.5g | N | N | 330023942 | BEVACIZUMAB + IRINOTECAN + TEMOZOLOMIDE |
| 330009025 | 330009167 | 1.71 | null | Palliative (P) | 2016-03-12 | 2016-04-02 | ALL UKALL60+ TRIAL | 02 | N | 330023942 | CARBOPLATIN + CETUXIMAB + FU |
| 330009026 | 330009168 | 1.8 | 71.5 | Palliative (P) | 2016-01-08 | 2016-01-08 | AML17 TRIAL | N | N | 330023962 | AML17 TRIAL |
| 330009027 | 330005822 | 1.63 | 48.3 | Curative (C) | 2014-03-08 | 2014-03-08 | BEP 5 Day | N | N | 330023981 | IFOSFAMIDE + VINCRISTINE |
| 330009028 | 330010981 | 1.67 | 9.5 | Palliative (P) | 2016-11-09 | 2016-12-11 | Cladribine (subcut) 5 days | 02 | N | 330023993 | UKALL 2011 |
| 330009029 | 330005823 | 0 | 95.1 | null | 2017-05-28 | 2017-06-15 | ICE (no GCSF) | Y | N | 330023994 | DACARBAZINE |
| 330009030 | 330005824 | 1.65 | 60.4 | Palliative (P) | 2013-07-04 | 2013-07-05 | CYCLOPHOSPHAMIDE + DOXORUBICIN | 2 | N | 330023994 | CYTARABINE |
| 330009031 | 330005828 | 1.6 | null | Curative (C) | 2017-07-21 | 2017-07-21 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 330024004 | PAZOPANIB |
| 330009032 | 330005829 | 0 | null | Curative (C) | 2016-04-11 | 2016-04-18 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 2 | N | 330024008 | BENDAMUSTINE |
| 330009036 | 330005831 | 1.51 | 89.25 | Curative (C) | 2015-05-27 | 2015-06-14 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | N | 330024059 | VDC |
| 330009037 | 330005831 | 1.77 | 86.6 | Curative (C) | 2017-09-28 | 2017-10-03 | VINCRISTINE | null | null | 330024059 | BEP |
| 330009038 | 330005831 | 1.58 | 53.1 | Palliative (P) | 2017-01-31 | 2017-04-24 | Clofarabine + Cytarabine | N | N | 330024059 | CARBOPLATIN + CETUXIMAB + FU |
| 330009039 | 330005833 | 1.69 | 72.2 | Palliative (P) | null | 2013-12-26 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 330024076 | IFOSFAMIDE + LIPOSOMAL DOXORUBICIN |
| 330009040 | 330012883 | 1.78 | 92.2 | Neo-adjuvant (N) | 2016-04-19 | 2016-04-24 | IMMUNOGLOBULIN | N | N | 330024098 | CISPLATIN + GEMCITABINE |
| 330009041 | 330005834 | null | 23.6 | Curative (C) | 2013-04-02 | 2013-09-14 | CYCLOPHOSPHAMIDE | N | N | 330024100 | KESTREL TRIAL |
| 330009042 | 330005834 | 0 | 95.9 | Palliative (P) | 2018-01-05 | 2018-03-26 | Lomustine | N | N | 330024100 | LOMUSTINE + PROCARBAZINE |
| 330009043 | 330005835 | 1.65 | 52.5 | Palliative (P) | 2016-02-13 | 2016-10-30 | AML 19 TRIAL | 02 | N | 330024112 | PONATINIB |
| 330009044 | 330005835 | 1.7 | 66.6 | Disease modification (D) | 2014-11-12 | 2014-11-15 | BEP 5 Day | N | N | 330024112 | FCR |
| 330009045 | 330005835 | 1.62 | 60.5 | Palliative (P) | null | 2017-07-17 | DHAP | N | N | 330024112 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330009046 | 330005837 | 1.75 | null | Palliative (P) | 2015-12-28 | 2016-01-22 | VIDE | null | N | 330024124 | CARBOPLATIN + VINCRISTINE |
| 330009047 | 330005837 | 1.79 | 74 | Curative (C) | 2014-03-18 | 2014-03-19 | Cytarabine Low Dose | 02 | N | 330024124 | IBRUTINIB |
| 330009048 | 330009180 | 1.76 | 57.5 | Adjuvant (A) | 2016-09-20 | 2016-11-07 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 330024126 | HYDROXYCARBAMIDE |
| 330009049 | 330009180 | 1.58 | 7.7 | Curative (C) | null | 2018-02-26 | Cyclophosphamide High Dose | N | N | 330024126 | LENALIDOMIDE |
| 330009050 | 330005839 | 0 | null | null | 2013-11-25 | 2013-12-08 | CARBOPLATIN + CETUXIMAB + FU | 02 | N | 330024135 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009051 | 330005840 | 1.67 | 65 | null | 2017-04-12 | 2017-06-03 | IMATINIB | N | N | 330024135 | DASATINIB |
| 330009052 | 330005841 | 1.71 | 23.8 | Palliative (P) | 2013-06-11 | 2013-06-11 | Mitotane 4 - 4.5g | N | N | 330024141 | CASPS TRIAL |
| 330009053 | 330005842 | 1.41 | 91 | Disease modification (D) | 2013-03-16 | 2013-03-19 | Nilotinib | null | N | 330024159 | BORTEZOMIB + PANOBINOSTAT |
| 330009054 | 330005842 | 1.86 | 64.5 | Palliative (P) | 2015-07-06 | 2015-07-08 | CETUXIMAB + CISPLATIN + FU | 2 | N | 330024159 | DACARBAZINE |
| 330009057 | 330009184 | 1.78 | 82 | Disease modification (D) | 2017-05-13 | 2017-06-24 | IPO | N | null | 330024179 | CARBOPLATIN + CETUXIMAB + FU |
| 330009058 | 330005846 | 1.7 | 60 | null | 2015-07-04 | 2015-07-08 | GEMCITABINE | N | null | 330024185 | CARBOPLATIN + CETUXIMAB + FU |
| 330009059 | 330005848 | 1.76 | 74 | Palliative (P) | 2017-06-15 | 2017-09-18 | Midostaurin | N | N | 330024190 | LENALIDOMIDE |
| 330009060 | 330012561 | 1.61 | 59 | Curative (C) | 2014-07-21 | 2014-07-21 | VIDE | N | N | 330024194 | EMA/CO |
| 330009061 | 330005849 | 0 | 23.9 | Adjuvant (A) | 2017-06-19 | 2017-07-24 | Vemurafenib | N | N | 330024195 | FBC |
| 330009062 | 330005850 | 0 | null | Adjuvant (A) | 2017-11-07 | 2017-12-11 | EMA/CO | null | N | 330024210 | CASPS TRIAL |
| 330009063 | 330005851 | 1.76 | 100.7 | null | 2015-03-19 | 2015-03-23 | Doxorubicin + Methotrexate | 2 | N | 330024234 | VIDE |
| 330009064 | 330009189 | 0 | 45.6 | Neo-adjuvant (N) | 2015-09-28 | 2015-10-07 | BENDAMUSTINE | N | N | 330024239 | BEP |
| 330009065 | 330005853 | 1.77 | 91.6 | Curative (C) | 2013-10-10 | 2013-10-16 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | 02 | N | 330024241 | INTERFERON |
| 330009066 | 330005855 | 1.61 | 30.6 | Palliative (P) | 2017-05-09 | 2017-05-12 | EP | null | N | 330024241 | UKALL2014 |
| 330009067 | 330005856 | null | 54.5 | Adjuvant (A) | null | 2013-06-27 | CNS LGG 2004 03 vinc weekly+ carbo | null | N | 330024258 | EMA/CO |
| 330009068 | 330010997 | 1.82 | 74 | Neo-adjuvant (N) | 2013-11-25 | 2013-12-16 | MERCAPTOPURINE + METHOTREXATE | N | N | 330024269 | BENDAMUSTINE |
| 330009069 | 330005859 | 1.83 | 84.4 | null | 2017-06-09 | 2017-06-09 | CETUXIMAB + CISPLATIN + FU | 2 | N | 330024272 | TOPOTECAN |
| 330009070 | 330005861 | null | 55.4 | Curative (C) | 2015-11-30 | 2015-11-30 | Dacarbazine | 2 | N | 330024278 | CAPECITABINE + CISPLATIN |
| 330009071 | 330005862 | 1.65 | 65.4 | Palliative (P) | 2019-01-06 | 2019-01-27 | CHLORAMBUCIL + RITUXIMAB | N | N | 330024281 | FLUOROURACIL + MITOMYCIN |
| 330009072 | 330005866 | 1.6 | 60.8 | Palliative (P) | 2013-01-24 | 2013-01-31 | Temozolomide + RT | N | N | 330024283 | VIDE |
| 330009074 | 330009198 | 1.63 | null | Curative (C) | 2013-12-01 | 2013-12-01 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330024298 | BEP |
| 330009075 | 330005868 | null | 48.6 | Curative (C) | 2014-12-15 | 2014-12-15 | Ifosfamide | 02 | null | 330024307 | CHOP R |